Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance
Paragon 28, a leading medical device company, reported a record net revenue of $61.1 million for the first quarter of 2024, up 17.4% from the same period in 2023. The company also reaffirmed its 2024 net revenue guidance of $249 million to $259 million, expecting 15.1% to 19.7% growth compared to 2023. Despite a decrease in gross profit margin and an increase in operating expenses, the company remains optimistic about sustainable growth driven by new product launches and expanded commercial channels.
Record net revenue of $61.1 million for the first quarter of 2024, a 17.4% increase from 2023.
Reaffirmed 2024 net revenue guidance of $249 million to $259 million, expecting 15.1% to 19.7% growth compared to 2023.
Increased surgeon activity in the U.S. and internationally, with expanding commercial channels and new product excitement driving growth.
Gross profit margin decreased to 80.0% in the first quarter of 2024 from 82.9% in 2023.
Operating expenses increased to $61.8 million in the first quarter of 2024 compared to $50.9 million in 2023.
Net loss of $15.2 million in the first quarter of 2024, compared to a net loss of $9.1 million in 2023.
Adjusted EBITDA loss of $5.5 million in the first quarter of 2024, a decrease from a $1.4 million loss in 2023.
Insights
First Quarter 2024 Financial Results
-
Consolidated net revenue for the first quarter of 2024 was a record
$61.1 million 17.4% reported and constant currency growth over the first quarter of 2023. Foreign currency impact on first quarter 2024 reported net revenue growth was not material.-
U.S. net revenue for the first quarter of 2024 was$51.1 million 13.5% over the first quarter of 2023. -
International net revenue for the first quarter of 2024 was a record
$10.0 million 42.2% and42.5% reported and constant currency growth, respectively, over the first quarter of 2023.
-
-
Gross profit margin was
80.0% for the first quarter of 2024 compared to82.9% in the first quarter of 2023. -
Operating expenses were
$61.8 million 21.5% , compared to$50.9 million -
Net loss was
$15.2 million $9.1 million -
Adjusted EBITDA was a
$5.5 million $4.1 million $1.4 million
“We are off to a strong start in 2024 and continue to see increased surgeon activity in the
2024 Net Revenue Guidance
The Company reaffirms its prior 2024 net revenue guidance, and expects net revenue to be
The Company’s 2024 net revenue guidance assumes foreign currency translation rates remain consistent with current foreign currency translation rates.
Webcast and Conference Call Information
Paragon 28 will host a conference call to discuss first quarter 2024 financial results on Wednesday, May 8, 2024, at 2:30 p.m. Mountain Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 483904. Live audio of the webcast will be available on the “Investors” section of the company’s website at ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Paragon 28, Inc.
Based in
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot and ankle patients, its estimated net revenue for full year 2024. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Paragon 28’s business in general, see Paragon 28’s current and future reports filed with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Use of Non-GAAP Financial Measures and Their Limitations
In addition to our results and measures of performance determined in accordance with
Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We define Adjusted EBITDA as earnings (loss) before interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, employee stock purchase plan expense, non-recurring expenses, and certain other non-cash expenses.
We believe that Adjusted EBITDA, together with a reconciliation to net income, helps identify underlying trends in our business and helps investors make comparisons between our company and other companies that may have different capital structures, tax rates, or different forms of employee compensation. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to a key financial metric used by our management in its financial and operational decision-making. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider these measures in isolation or as a substitute for analysis of our financial results as reported under
- other companies, including companies in our industry which have similar business arrangements, may report Adjusted EBITDA, or similarly titled measures but calculate them differently, which reduces their usefulness as comparative measures;
- although depreciation and amortization expenses are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements;
- Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock-based compensation; and
- Adjusted EBITDA does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments on our debt that we may incur.
Additionally, we report revenue growth on a constant-currency basis in order to facilitate period-to-period comparisons of results without regard to the impact of fluctuating foreign currency exchange rates. The term foreign currency exchange rates refers to the exchange rates used to translate the company's operating results for all countries where the functional currency is not the
The company believes disclosure of constant-currency revenue growth rates is helpful to investors because it facilitates period-to-period comparisons. However, constant-currency revenue growth rates are non-GAAP financial measures and are not meant to be considered as an alternative or substitute for comparable measures prepared in accordance with GAAP. Constant-currency growth has no standardized meaning prescribed by GAAP and should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP. We calculate constant-currency growth rates by translating local currency amounts in the current period at actual foreign exchange rates for the prior period.
Because of these and other limitations, you should consider our non-GAAP measures only as supplemental to other GAAP-based financial measures.
PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, unaudited) |
||||||||
|
|
March 31, 2024 |
|
December 31, 2023 |
||||
ASSETS |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash |
|
$ |
58,222 |
|
|
$ |
75,639 |
|
Trade receivables, net of allowance for doubtful accounts of |
|
|
40,262 |
|
|
|
37,323 |
|
Inventories, net |
|
|
104,298 |
|
|
|
98,062 |
|
Income taxes receivable |
|
|
597 |
|
|
|
794 |
|
Other current assets |
|
|
4,013 |
|
|
|
3,997 |
|
Total current assets |
|
|
207,392 |
|
|
|
215,815 |
|
|
|
|
|
|
||||
Property and equipment, net |
|
|
75,701 |
|
|
|
74,122 |
|
Intangible assets, net |
|
|
21,458 |
|
|
|
21,674 |
|
Goodwill |
|
|
25,465 |
|
|
|
25,465 |
|
Deferred income taxes |
|
|
678 |
|
|
|
705 |
|
Other assets |
|
|
3,900 |
|
|
|
2,918 |
|
Total assets |
|
$ |
334,594 |
|
|
$ |
340,699 |
|
|
|
|
|
|
||||
LIABILITIES & STOCKHOLDERS' EQUITY |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
29,224 |
|
|
$ |
21,696 |
|
Accrued expenses |
|
|
26,823 |
|
|
|
27,781 |
|
Other current liabilities |
|
|
909 |
|
|
|
883 |
|
Current maturities of long-term debt |
|
|
640 |
|
|
|
640 |
|
Income taxes payable |
|
|
450 |
|
|
|
243 |
|
Total current liabilities |
|
|
58,046 |
|
|
|
51,243 |
|
|
|
|
|
|
||||
Long-term liabilities: |
|
|
|
|
||||
Long-term debt net, less current maturities |
|
|
109,847 |
|
|
|
109,799 |
|
Other long-term liabilities |
|
|
1,356 |
|
|
|
1,048 |
|
Deferred income taxes |
|
|
231 |
|
|
|
233 |
|
Income taxes payable |
|
|
638 |
|
|
|
635 |
|
Total liabilities |
|
|
170,118 |
|
|
|
162,958 |
|
|
|
|
|
|
||||
Stockholders' equity: |
|
|
|
|
||||
Common stock, |
|
|
828 |
|
|
|
827 |
|
Additional paid in capital |
|
|
301,459 |
|
|
|
298,394 |
|
Accumulated deficit |
|
|
(130,864 |
) |
|
|
(115,630 |
) |
Accumulated other comprehensive loss |
|
|
(965 |
) |
|
|
132 |
|
Treasury stock, at cost; 913,519 shares as of March 31, 2024 and December 31, 2023 |
|
|
(5,982 |
) |
|
|
(5,982 |
) |
Total stockholders' equity |
|
|
164,476 |
|
|
|
177,741 |
|
Total liabilities & stockholders' equity |
|
$ |
334,594 |
|
|
$ |
340,699 |
|
PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, unaudited) |
|||||||
|
Three Months Ended March 31, |
||||||
|
2024 |
|
2023 |
||||
Net revenue |
$ |
61,082 |
|
|
$ |
52,036 |
|
Cost of goods sold |
|
12,186 |
|
|
|
8,906 |
|
Gross profit |
|
48,896 |
|
|
|
43,130 |
|
|
|
|
|
||||
Operating expenses: |
|
|
|
||||
Research and development costs |
|
7,584 |
|
|
|
7,049 |
|
Selling, general, and administrative |
|
54,215 |
|
|
|
43,820 |
|
Total operating expenses |
|
61,799 |
|
|
|
50,869 |
|
Operating loss |
|
(12,903 |
) |
|
|
(7,739 |
) |
|
|
|
|
||||
Other income (expense): |
|
|
|
||||
Other income (expense), net |
|
515 |
|
|
|
(179 |
) |
Interest expense, net |
|
(2,622 |
) |
|
|
(1,205 |
) |
Total other expense, net |
|
(2,107 |
) |
|
|
(1,384 |
) |
Loss before income taxes |
|
(15,010 |
) |
|
|
(9,123 |
) |
Income tax expense (benefit) |
|
224 |
|
|
|
(71 |
) |
Net loss |
$ |
(15,234 |
) |
|
$ |
(9,052 |
) |
PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited) |
||||||||
|
|
Three Months Ended March 31, |
||||||
|
|
2024 |
|
2023 |
||||
Cash flows from operating activities |
|
|
|
|
||||
Net loss |
|
$ |
(15,234 |
) |
|
$ |
(9,052 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
4,258 |
|
|
|
3,117 |
|
Provision for excess and obsolete inventories |
|
|
471 |
|
|
|
293 |
|
Stock-based compensation |
|
|
3,088 |
|
|
|
3,182 |
|
Change in fair value |
|
|
(519 |
) |
|
|
80 |
|
Other |
|
|
(785 |
) |
|
|
100 |
|
Changes in other assets and liabilities, net of acquisitions: |
|
|
|
|
||||
Accounts receivable |
|
|
(3,099 |
) |
|
|
441 |
|
Inventories |
|
|
(7,044 |
) |
|
|
(8,435 |
) |
Accounts payable |
|
|
7,441 |
|
|
|
5,592 |
|
Accrued expenses |
|
|
194 |
|
|
|
(877 |
) |
Accrued legal settlement |
|
|
— |
|
|
|
(9,000 |
) |
Income tax receivable/payable |
|
|
398 |
|
|
|
132 |
|
Other assets and liabilities |
|
|
(162 |
) |
|
|
367 |
|
Net cash used in operating activities |
|
|
(10,993 |
) |
|
|
(14,060 |
) |
|
|
|
|
|
||||
Cash flows from investing activities |
|
|
|
|
||||
Purchases of property and equipment |
|
|
(5,817 |
) |
|
|
(7,521 |
) |
Proceeds from sale of property and equipment |
|
|
292 |
|
|
|
223 |
|
Purchases of intangible assets |
|
|
(253 |
) |
|
|
(254 |
) |
Net cash used in investing activities |
|
|
(5,778 |
) |
|
|
(7,552 |
) |
|
|
|
|
|
||||
Cash flows from financing activities |
|
|
|
|
||||
Payments on long-term debt |
|
|
(160 |
) |
|
|
(197 |
) |
Payments of debt issuance costs |
|
|
— |
|
|
|
(7 |
) |
Proceeds from issuance of common stock, net of issuance costs |
|
|
— |
|
|
|
68,449 |
|
Options exercised |
|
|
298 |
|
|
|
1,622 |
|
RSU vesting, taxes paid |
|
|
(400 |
) |
|
|
— |
|
Payments on earnout liability |
|
|
(1,000 |
) |
|
|
(500 |
) |
Net cash (used in) provided by financing activities |
|
|
(1,262 |
) |
|
|
69,367 |
|
|
|
|
|
|
||||
Effect of exchange rate changes on cash |
|
|
616 |
|
|
|
(340 |
) |
Net (decrease) increase in cash |
|
|
(17,417 |
) |
|
|
47,415 |
|
Cash at beginning of period |
|
|
75,639 |
|
|
|
38,468 |
|
Cash at end of period |
|
$ |
58,222 |
|
|
$ |
85,883 |
|
PARAGON 28, INC. AND SUBSIDIARIES RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (in thousands, unaudited) |
||||||||
|
|
Three Months Ended March 31, |
||||||
|
|
2024 |
|
2023 |
||||
|
|
(in thousands) |
||||||
Net loss |
|
$ |
(15,234 |
) |
|
$ |
(9,052 |
) |
Interest expense, net |
|
|
2,622 |
|
|
|
1,205 |
|
Income tax expense (benefit) |
|
|
224 |
|
|
|
(71 |
) |
Depreciation and amortization expense |
|
|
4,258 |
|
|
|
3,117 |
|
Stock based compensation expense |
|
|
3,088 |
|
|
|
3,182 |
|
Employee stock purchase plan expense |
|
|
80 |
|
|
|
122 |
|
Change in fair value (1) |
|
|
(519 |
) |
|
|
80 |
|
Adjusted EBITDA |
|
$ |
(5,481 |
) |
|
$ |
(1,417 |
) |
| (1) | Represents non-cash change in the fair value of our interest rate swap contract for the three months ended March 31, 2024 and earnout liabilities for the three months ended March 31, 2023 |
PARAGON 28, INC. AND SUBSIDIARIES Constant-Currency Revenue Growth (in thousands, unaudited) |
|||||||||
|
|
|
|
||||||
|
Three Months Ended March 31, |
Change |
|||||||
|
2024 |
2023 |
% |
||||||
Total Consolidated Revenues |
|
|
|
||||||
As Reported |
$ |
61,082 |
$ |
52,036 |
17.4 |
% |
|||
Impact of foreign currency exchange rates |
|
23 |
|
— |
* |
||||
Constant-currency net revenues |
$ |
61,105 |
$ |
52,036 |
17.4 |
% |
|||
|
|
|
|
||||||
Total International Revenues |
|
|
|
||||||
As Reported |
$ |
10,031 |
$ |
7,055 |
42.2 |
% |
|||
Impact of foreign currency exchange rates |
|
23 |
|
— |
* |
||||
Constant-currency net revenues |
$ |
10,054 |
$ |
7,055 |
42.5 |
% |
|||
* Not meaningful
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508954958/en/
Investor Contact:
Matt Brinckman
Senior Vice President, Strategy and Investor Relations
mbrinckman@paragon28.com
Source: Paragon 28, Inc.
FAQ
What was Paragon 28's net revenue for the first quarter of 2024?
What is Paragon 28's 2024 net revenue guidance?
What was the gross profit margin for Paragon 28 in the first quarter of 2024?
What was Paragon 28's net loss in the first quarter of 2024?
What was the adjusted EBITDA in the first quarter of 2024 for Paragon 28?
